We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Compassionate Use of Sodium Stibogluconate (Pentostam) for Cutaneous and Mucocutaneous New World Leishmaniasis

Expanded access is currently available for this treatment.
Verified December 2014 by University of California, San Francisco
Sponsor:
ClinicalTrials.gov Identifier:
NCT00508963
First Posted: July 30, 2007
Last Update Posted: December 15, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
University of California, San Francisco
July 27, 2007
July 30, 2007
December 15, 2014
 
Compassionate Use of Sodium Stibogluconate (Pentostam) for Cutaneous and Mucocutaneous New World Leishmaniasis
Patients with biopsy proven new world cutaneous or mucocutaneous leishmaniasis will be treated with sodium stibogluconate (Pentostam).
Not Provided
Expanded Access
Drug: sodium stibogluconate (Pentostam)
20 mg/kg IV every day for 20 or 28 days
Not Provided
 
Available
Contact: Jane E Koehler, MA, MD 415-476-3536 jkoehler@medicine.ucsf.edu
United States
 
 
NCT00508963
University of California, San Francisco
University of California, San Francisco
Not Provided
Principal Investigator: Brian Schwartz, MD University of CA at San Francisco
Principal Investigator: Kanade Shinkai, MD University of CA at San Francisco
University of California, San Francisco
December 2014